Aditxt, Inc. (ADTX)
NASDAQ: ADTX · IEX Real-Time Price · USD
6.63
+1.81 (37.55%)
At close: Dec 29, 2023, 4:00 PM
5.10
-1.53 (-23.08%)
After-hours: Dec 29, 2023, 7:59 PM EST
Aditxt Revenue
Aditxt had revenue of $749.48K in the twelve months ending September 30, 2023, down -12.15% year-over-year. Revenue in the quarter ending September 30, 2023 was $124.49K, a -61.47% decrease year-over-year. In the year 2022, Aditxt had annual revenue of $933.72K with 788.96% growth.
Revenue (ttm)
$749.48K
Revenue Growth
-12.15%
P/S Ratio
11.05
Revenue / Employee
$12,286
Employees
61
Market Cap
8.28M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 933.72K | 828.68K | 788.96% |
| Dec 31, 2021 | 105.03K | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Applied DNA Sciences | 13.37M |
| Aravive | 7.00M |
| Aeterna Zentaris | 6.86M |
| Vaccinex | 795.00K |
| ABVC BioPharma | 739.26K |
| Cyclerion Therapeutics | 608.00K |
| BioRestorative Therapies | 130.20K |
| Benitec Biopharma | 75.00K |
ADTX News
- 2 days ago - Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules - Business Wire
- 13 days ago - EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM - Business Wire
- 19 days ago - Aditxt (ADTX) stock price just soared but gains could be brief - Invezz
- 19 days ago - ADTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aditxt, Inc. Is Fair to Shareholders - Business Wire
- 19 days ago - Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally - Business Wire
- 3 months ago - Aditxt, Inc. to Present at 8th Annual Dawson James Conference - GlobeNewsWire
- 3 months ago - Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform - Business Wire
- 4 months ago - Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023 - Business Wire